11:53 AM EST - Amorfix Life Sciences Ltd. : announced today that the Company has signed an agreement granting an exclusive worldwide license for its preclinical Alzheimer's disease diagnostic test, the Amorfix Aggregated Abeta Assay (the A4) to JSW Lifesciences GmbH, a contract research organization specializing in Alzheimer's disease and other neurodegenerative disorders. Under the terms of the agreement, JSW will market and perform the A4 assay as a service in the area of preclinical Alzheimer's disease studies. The agreement includes a commitment to minimum annual sales and Amorfix will receive a percentage of net sales. The Agreement was signed after the completion of due diligence on the technology by JSW, conducted pursuant to the Letter of Intent previously executed by the parties. Amorfix Life Sciences Ltd.
shares T.AMF are trading unchanged at $0.45.
